Quantisnow Logo
Dashboard

SEC Form SC 13G/A filed by AlloVir Inc. (Amendment)

$ALVR
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Get the next $ALVR alert in real time by email
SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No.3 ALLOVIR INC COMMON STOCK Cusip #019818103 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #019818103 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 7,045,961 Item 6: 0 Item 7: 7,046,373 Item 8: 0 Item 9: 7,046,373 Item 11: 7.563% Item 12: HC Cusip #019818103 Item 1: Reporting Person - Abigail P. Johnson Item 2: (a) [ ] (b) [ ] Item 4: United States of America Item 5: 0 Item 6: 0 Item 7: 7,046,373 Item 8: 0 Item 9: 7,046,373 Item 11: 7.563% Item 12: IN Item 1(a). Name of Issuer: ALLOVIR INC Item 1(b). Address of Issuer's Principal Executive Offices: 1100 WINTER STREET WALTHAM, MA 02451 USA Item 2(a). Name of Person Filing: FMR LLC Item 2(b). Address or Principal Business Office or, if None, Residence: 245 Summer Street, Boston, Massachusetts 02210 Item 2(c). Citizenship: Not applicable Item 2(d). Title of Class of Securities: COMMON STOCK Item 2(e). CUSIP Number: 019818103 Item 3. This statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c) and the person filing, FMR LLC, is a parent holding company in accordance with Section 240.13d-1(b)(1)(ii)(G). (Note: See Exhibit A). Item 4. Ownership (a) Amount Beneficially Owned: 7,046,373 (b) Percent of Class: 7.563% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: Please see the responses to Items 5 and 6 on the cover page (ii) shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: 7,046,373 (iv) shared power to dispose or to direct the disposition of: 0 Item 5. Ownership of Five Percent or Less of a Class. Not applicable. Item 6. Ownership of More than Five Percent on Behalf of Another Person. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of ALLOVIR INC. No one other person's interest in the COMMON STOCK of ALLOVIR INC is more than five percent of the total outstanding COMMON STOCK. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. See attached Exhibit A. Item 8. Identification and Classification of Members of the Group. Not applicable. Item 9. Notice of Dissolution of Group. Not applicable. Item 10. Certifications. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing orinfluencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. February 9, 2023 Date /s/ Stephanie J. Brown Signature Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. Exhibit A Pursuant to the instructions in Item 7 of Schedule 13G, the following table lists the identity and Item 3 classification, if applicable, of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Entity ITEM 3 Classification Fidelity Management & Research Company LLC IA Fidelity Management Trust Company BK Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies (collectively, the "FMR Reporters"). This filing does not reflect securities, if any, beneficially owned by certain other companies whose beneficial ownership of securities is disaggregated from that of the FMR Reporters in accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998). RULE 13d-1(k)(1) AGREEMENT The undersigned persons, on February 9, 2023, agree and consent to the joint filing on their behalf of this Schedule 13G in connection with their beneficial ownership of the COMMON STOCK of ALLOVIR INC at December 30, 2022. FMR LLC By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* Abigail P. Johnson By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January, 26, 2023, by and on behalf of Abigail P. Johnson** * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. ** This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 31, 2023, accession number: 0000315066-23-000038.
Get the next $ALVR alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ALVR

DatePrice TargetRatingAnalyst
12/26/2023$17.00 → $1.00Buy → Underperform
BofA Securities
12/22/2023Outperform → Market Perform
Leerink Partners
12/22/2023Overweight → Underweight
JP Morgan
12/22/2023Overweight → Neutral
Piper Sandler
8/18/2023$17.00Buy
BofA Securities
2/10/2022$32.00 → $30.00Outperform
SVB Leerink
1/18/2022$48.00 → $45.00Overweight
Morgan Stanley
12/17/2021$37.00 → $32.00Outperform
SVB Leerink
More analyst ratings

$ALVR
 Press Releases

Fastest customizable press release news feed in the world

See more

  • AlloVir, Inc. investors: Please contact the Portnoy Law Firm to recover your losses; March 19, 2024 deadline

    Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, March 04, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises AlloVir, Inc. ("AlloVir or the "Company") (NASDAQ:ALVR) investors that a lawsuit was filed on behalf of investors that purchased AlloVir securities between March 22, 2022 and December 21, 2023, inclusive (the "Class Period"). Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: lesley@portnoylaw.com, to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' options fo

    $ALVR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

  • AlloVir, Inc. investors: Please contact the Portnoy Law Firm to recover your losses; March 19, 2024 deadline

    Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Feb. 28, 2024 (GLOBE NEWSWIRE) -- ​The Portnoy Law Firm advises AlloVir, Inc. ("AlloVir" or the "Company") (NASDAQ:ALVR) investors that a lawsuit was filed on behalf of investors that purchased AlloVir securities between March 22, 2022 and December 21, 2023, inclusive (the "Class Period"). Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: lesley@portnoylaw.com, to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' optio

    $ALVR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

  • AlloVir Provides Updates on Phase 3 Clinical Development Program for Posoleucel, an Allogeneic Virus-Specific T Cell Therapy

    Company to discontinue its three Phase 3 posoleucel studies following separate, pre-planned DSMB futility analyses concluding the studies were unlikely to meet their primary endpoints; no safety concerns identified Company to prioritize capital preservation and review strategic options AlloVir reported $213.3 million in cash, cash equivalents, and short-term investments as of September 30, 2023 WALTHAM, Mass., Dec. 22, 2023 (GLOBE NEWSWIRE) -- AlloVir, Inc. (NASDAQ:ALVR), an allogeneic T cell immunotherapy company, today provided an update on its three Phase 3 clinical trials with posoleucel, an investigational off-the-shelf multi-virus-s

    $ALVR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$ALVR
 Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$ALVR
 Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$ALVR
 SEC Filings

See more

$ALVR
 Leadership Updates

Live Leadership Updates

See more

  • AlloVir, Inc. investors: Please contact the Portnoy Law Firm to recover your losses; March 19, 2024 deadline

    Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, March 04, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises AlloVir, Inc. ("AlloVir or the "Company") (NASDAQ:ALVR) investors that a lawsuit was filed on behalf of investors that purchased AlloVir securities between March 22, 2022 and December 21, 2023, inclusive (the "Class Period"). Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: lesley@portnoylaw.com, to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' options fo

    $ALVR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

  • AlloVir, Inc. investors: Please contact the Portnoy Law Firm to recover your losses; March 19, 2024 deadline

    Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Feb. 28, 2024 (GLOBE NEWSWIRE) -- ​The Portnoy Law Firm advises AlloVir, Inc. ("AlloVir" or the "Company") (NASDAQ:ALVR) investors that a lawsuit was filed on behalf of investors that purchased AlloVir securities between March 22, 2022 and December 21, 2023, inclusive (the "Class Period"). Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: lesley@portnoylaw.com, to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' optio

    $ALVR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

  • AlloVir Announces Appointment of Cintia Piccina, PharmD, MBA, as Chief Commercial Officer

    - Industry veteran brings more than 25 years of global commercial leadership and cell therapy expertise to AlloVir to build out company's commercial strategy and capabilities - AlloVir (NASDAQ:ALVR), a late-clinical stage allogeneic T cell immunotherapy company, today announced the appointment of Cintia Piccina, PharmD, MBA, as the company's Chief Commercial Officer, effective June 12, 2023. Ms. Piccina will drive the global commercialization strategy for AlloVir, with a focus on its lead product, posoleucel, and be responsible for building a commercial team in anticipation of a 2025 launch. "Cintia is an accomplished executive with a track record of successful cell therapy and oncology

    $ALVR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$ALVR
 Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more